Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
Animal model
Biomarker
Choroidal nevi
Circulating tumor DNA
Clinical specimens
In vitro study
Liquid biopsy
Mutated driver genes
Uveal melanoma
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
16 Jun 2021
16 Jun 2021
Historique:
received:
05
03
2021
accepted:
16
05
2021
entrez:
17
6
2021
pubmed:
18
6
2021
medline:
29
12
2021
Statut:
epublish
Résumé
Uveal melanoma (UM) is the most common intraocular tumor in adults. Despite good primary tumor control, up to 50% of patients develop metastasis, which is lethal. UM often presents asymptomatically and is usually diagnosed by clinical examination and imaging, making it one of the few cancer types diagnosed without a biopsy. Hence, alternative diagnostic tools are needed. Circulating tumor DNA (ctDNA) has shown potential as a liquid biopsy target for cancer screening and monitoring. The aim of this study was to evaluate the feasibility and clinical utility of ctDNA detection in UM using specific UM gene mutations. We used the highly sensitive digital droplet PCR (ddPCR) assay to quantify UM driver mutations (GNAQ, GNA11, PLCβ4 and CYSTLR2) in cell-free DNA (cfDNA). cfDNA was analyzed in six well established human UM cell lines with known mutational status. cfDNA was analyzed in the blood and aqueous humor of an UM rabbit model and in the blood of patients. Rabbits were inoculated with human UM cells into the suprachoroidal space, and mutated ctDNA was quantified from longitudinal peripheral blood and aqueous humor draws. Blood clinical specimens were obtained from primary UM patients (n = 14), patients presenting with choroidal nevi (n = 16) and healthy individuals (n = 15). The in vitro model validated the specificity and accuracy of ddPCR to detect mutated cfDNA from UM cell supernatant. In the rabbit model, plasma and aqueous humor levels of ctDNA correlated with tumor growth. Notably, the detection of ctDNA preceded clinical detection of the intraocular tumor. In human specimens, while we did not detect any trace of ctDNA in healthy controls, we detected ctDNA in all UM patients. We observed that UM patients had significantly higher levels of ctDNA than patients with nevi, with a strong correlation between ctDNA levels and malignancy. Noteworthy, in patients with nevi, the levels of ctDNA highly correlated with the presence of clinical risk factors. We report, for the first time, compelling evidence from in vitro assays, and in vivo animal model and clinical specimens for the potential of mutated ctDNA as a biomarker of UM progression. These findings pave the way towards the implementation of a liquid biopsy to detect and monitor UM tumors.
Sections du résumé
BACKGROUND
BACKGROUND
Uveal melanoma (UM) is the most common intraocular tumor in adults. Despite good primary tumor control, up to 50% of patients develop metastasis, which is lethal. UM often presents asymptomatically and is usually diagnosed by clinical examination and imaging, making it one of the few cancer types diagnosed without a biopsy. Hence, alternative diagnostic tools are needed. Circulating tumor DNA (ctDNA) has shown potential as a liquid biopsy target for cancer screening and monitoring. The aim of this study was to evaluate the feasibility and clinical utility of ctDNA detection in UM using specific UM gene mutations.
METHODS
METHODS
We used the highly sensitive digital droplet PCR (ddPCR) assay to quantify UM driver mutations (GNAQ, GNA11, PLCβ4 and CYSTLR2) in cell-free DNA (cfDNA). cfDNA was analyzed in six well established human UM cell lines with known mutational status. cfDNA was analyzed in the blood and aqueous humor of an UM rabbit model and in the blood of patients. Rabbits were inoculated with human UM cells into the suprachoroidal space, and mutated ctDNA was quantified from longitudinal peripheral blood and aqueous humor draws. Blood clinical specimens were obtained from primary UM patients (n = 14), patients presenting with choroidal nevi (n = 16) and healthy individuals (n = 15).
RESULTS
RESULTS
The in vitro model validated the specificity and accuracy of ddPCR to detect mutated cfDNA from UM cell supernatant. In the rabbit model, plasma and aqueous humor levels of ctDNA correlated with tumor growth. Notably, the detection of ctDNA preceded clinical detection of the intraocular tumor. In human specimens, while we did not detect any trace of ctDNA in healthy controls, we detected ctDNA in all UM patients. We observed that UM patients had significantly higher levels of ctDNA than patients with nevi, with a strong correlation between ctDNA levels and malignancy. Noteworthy, in patients with nevi, the levels of ctDNA highly correlated with the presence of clinical risk factors.
CONCLUSIONS
CONCLUSIONS
We report, for the first time, compelling evidence from in vitro assays, and in vivo animal model and clinical specimens for the potential of mutated ctDNA as a biomarker of UM progression. These findings pave the way towards the implementation of a liquid biopsy to detect and monitor UM tumors.
Identifiants
pubmed: 34134723
doi: 10.1186/s13046-021-01984-w
pii: 10.1186/s13046-021-01984-w
pmc: PMC8207750
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
196Subventions
Organisme : Consejo Nacional de Ciencia y Tecnología
ID : 739468
Références
Ophthalmology. 2007 Dec;114(12):2309-15
pubmed: 17498805
Eur J Ophthalmol. 1996 Oct-Dec;6(4):472-4
pubmed: 8997595
Oncotarget. 2016 Jan 26;7(4):4624-31
pubmed: 26683228
Ophthalmology. 2005 Oct;112(10):1784-9
pubmed: 16154197
Nature. 2009 Jan 29;457(7229):599-602
pubmed: 19078957
Cancer Metastasis Rev. 2017 Mar;36(1):109-140
pubmed: 28229253
Comput Struct Biotechnol J. 2018 Oct 09;16:370-378
pubmed: 30364656
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2823-8
pubmed: 18408179
J Med Genet. 2011 Dec;48(12):856-9
pubmed: 21941004
Int J Clin Exp Pathol. 2013 Jun 15;6(7):1230-44
pubmed: 23826405
Curr Eye Res. 2011 Apr;36(4):386-90
pubmed: 21284506
Biomol Detect Quantif. 2019 Feb 13;17:100078
pubmed: 30906693
JAMA Ophthalmol. 2013 Aug;131(8):993-1003
pubmed: 23681424
Cancer Cell. 2014 Jun 16;25(6):822-30
pubmed: 24882516
Ocul Oncol Pathol. 2021 Mar;7(1):1-16
pubmed: 33796511
Trends Mol Med. 2020 May;26(5):519-528
pubmed: 32359482
Curr Eye Res. 2017 Aug;42(8):1085-1093
pubmed: 28494168
N Engl J Med. 2010 Dec 2;363(23):2191-9
pubmed: 21083380
Clin Chem. 2020 Jan 1;66(1):149-160
pubmed: 31628139
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4740-4747
pubmed: 31731294
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175
pubmed: 29497459
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Oman J Ophthalmol. 2013 May;6(2):116-8
pubmed: 24082672
Mol Aspects Med. 2020 Apr;72:100828
pubmed: 31711714
Eye (Lond). 2007 Jun;21(6):752-9
pubmed: 16575415
Thorac Cancer. 2019 Dec;10(12):2218-2224
pubmed: 31602787
Int J Ophthalmol. 2020 Apr 18;13(4):599-605
pubmed: 32399411
Br J Cancer. 2017 Sep 5;117(6):884-887
pubmed: 28809862
Br J Ophthalmol. 2019 Oct;103(10):1441-1447
pubmed: 30523045
Semin Cancer Biol. 2021 Jun;71:65-85
pubmed: 32450140
Retina. 2019 Oct;39(10):1852-1860
pubmed: 30883534
Genes Chromosomes Cancer. 2018 Mar;57(3):123-139
pubmed: 29205637
Mol Oncol. 2014 Dec;8(8):1508-20
pubmed: 24994677
Cancer Biomark. 2020;27(1):29-37
pubmed: 31658042
Biomol Detect Quantif. 2019 Mar 18;17:100087
pubmed: 30923679
Biomed Res Int. 2017;2017:5986129
pubmed: 28484715
Ophthalmology. 2017 Oct;124(10):1523-1531
pubmed: 28495150
Cancers (Basel). 2019 Jul 30;11(8):
pubmed: 31366043
Cancer Med. 2017 Oct;6(10):2297-2307
pubmed: 28940814
Sci Rep. 2019 Mar 26;9(1):5220
pubmed: 30914716
Ann Oncol. 2019 Oct 1;30(10):1580-1590
pubmed: 31373349
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424
pubmed: 30796368
Lancet Oncol. 2014 Apr;15(4):406-14
pubmed: 24636208
Sci Transl Med. 2015 Jun 24;7(293):293ra104
pubmed: 26109104
Int J Cancer. 1995 Jul 17;62(2):155-61
pubmed: 7622289
Melanoma Res. 2002 Dec;12(6):593-9
pubmed: 12459649
Indian J Ophthalmol. 2019 Dec;67(12):2035-2042
pubmed: 31755445
Prog Retin Eye Res. 2020 Mar;75:100800
pubmed: 31563544
Nat Genet. 2016 Jun;48(6):675-80
pubmed: 27089179
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Clin Ophthalmol. 2020 Jan 20;14:157-169
pubmed: 32021081
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4376-82
pubmed: 16303923
J Exp Clin Cancer Res. 2018 Dec 27;37(1):324
pubmed: 30591064